Medpace (MEDP)
(Real Time Quote from BATS)
$391.16 USD
-9.05 (-2.26%)
Updated Apr 30, 2024 01:16 PM ET
1-Strong Buy of 5 1
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
MEDP 391.16 -9.05(-2.26%)
Will MEDP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MEDP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MEDP
Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?
Zacks Industry Outlook Highlights Elevance Health Medpace and Doximity
MEDP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
3 Medical Services Industry Stocks to Buy as Nursing Market Booms
Medpace (MEDP) Beats Q1 Earnings Estimates
Other News for MEDP
MEDP Crosses Above Average Analyst Target
Medpace price target raised by $11 at Guggenheim, here's why
Medpace price target raised by $8 at Baird, here's why
Medpace Holdings Inc (MEDP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
Medpace raised to Buy at Jefferies after Q1 earnings beat